JACOBS SOLUTIONS INC. (J) Stock News

Johnson & Johnson raised its full-year sales and earnings guidance after beating Q3 estimates, but the stock fell 6% due to disappointing medical device sales. Despite near-term concerns about the MedTech division and a planned DePuy Synthes spinoff, the company's strong oncology business growth (16%+ in Q3) and reliable 64-year dividend streak make it an attractive long-term buy at current valuations.

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

J.B. Hunt outlined plans to raise contractual rates to offset rising operational expenses including driver pay and medical costs. The company is shifting from spot rate adjustments to multiyear contract price increases, investing over $50 million in driver recruitment and capacity building, and seeing strong growth in its Dedicated Contract Services division with 970 trucks sold year-to-date. Long-term shareholder value depends on successfully enforcing higher rates during 2027 contract renewals.

Google launched its Project Suncatcher test satellite with four AI chips to orbit via SpaceX Falcon 9, testing whether AI chips can survive harsh space conditions. Meanwhile, Elon Musk has filed plans with the FCC for a million data center satellites to address AI's massive power consumption bottleneck. Altucher argues Musk is two decades ahead of competitors and identifies a small supplier providing critical data networking infrastructure as a potential key beneficiary.

AIBotics, Inc. completed its acquisition of NovaCore Labs' operating assets from PlayJamaica Limited, gaining drone systems, mapping equipment, robotics, and intellectual property. The deal, valued at $225,000 in Series B Preferred Stock with potential earn-outs up to $3.0 million based on revenue milestones, positions AIBotics to expand AI, drone, and automation services across Jamaica and the Caribbean region.

Pfizer declared its 352nd consecutive quarterly dividend with a 5.9% yield, significantly higher than the S&P 500 average of 1%. While the company faces patent cliffs on major drugs like Eliquis and Xeljanz this year, it maintains a robust pipeline focused on cancer treatments and generated $11 billion in free cash flow over the past four quarters, exceeding dividend payments. Management remains committed to maintaining and growing the dividend, though investors must have confidence in the company's ability to replace expiring patents with new pipeline drugs.

ExxonMobil expects a $4.5 billion boost to third-quarter earnings from strong refining margins, more than doubling its energy products segment earnings compared to Q2. Despite headwinds from lower oil prices, the company's integrated business model—combining upstream exploration, midstream logistics, and downstream refining—enables more resilient results. This demonstrates the strategic advantage of ExxonMobil's diversified approach compared to pure-play energy companies.

Nvidia's stock dropped 4% (losing $200 billion in market value) after OpenAI disclosed a $50 billion revenue run rate, $18 billion below market expectations. The miss raised concerns about AI demand growth and its impact on chip sales. Despite the decline, analysts view Nvidia as attractively priced at less than 14x forward earnings, with strong 70% guidance for fiscal 2028, suggesting the sell-off may present a buying opportunity.

Johnson & Johnson raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to exceed $100 billion in annual revenue for the first time. Strong pharmaceutical demand, particularly in cancer treatments, drove performance. However, the medical device segment faced headwinds with only 2.5% growth due to Middle East disruptions and China's bulk-buying program. Management plans to restore momentum through new product launches and is leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027.

A securities class action lawsuit has been filed against York Space Systems Inc. for investors who purchased stock during its January 2026 IPO and through May 11, 2026. The lawsuit alleges that York's IPO registration statement contained materially false or misleading statements regarding the functionality of its satellite software and failed to disclose that onboard mission and payload software was not fully functional before launch, which presented risks to its SDA contracts.

J.B. Hunt Transport Services reported Q3 2026 earnings of $1.82 per share, up 3.4% year-over-year, with revenues surging 20.4% to $3.68 billion. The Intermodal segment showed strong 20% revenue growth, while the brokerage business returned to profitability. However, operating margins contracted to 6.7% from 7.9% due to elevated driver costs, fuel expenses, and insurance claims. The company faces headwinds from cost pressures despite solid pricing improvements.

JPMorgan Chase reported Q3 2026 net income of $15.3 billion on $50.9 billion revenue. The bank is prioritizing organic growth over share buybacks, deploying AI tools internally while restricting external agents for security, and projects $107 billion in 2027 net interest income. Management highlights consumer resilience and steady execution across market conditions.

A class action lawsuit has been filed against Papa John's International, Inc. (NASDAQ: PZZA) alleging securities fraud. The complaint claims that company executives made materially false and misleading statements regarding the company's transformation efforts, market share losses, and competitive position during the period from August 7, 2025 to August 5, 2026. Investors who purchased Papa John's securities during this period are encouraged to join the lawsuit, with a lead plaintiff deadline of November 2, 2026.

Tesla unveiled its next-generation Roadster with SpaceX technology, featuring vertical climbing, hovering capabilities, and speeds up to 230 mph. While the vehicle won't significantly impact finances until 2028 production begins, the demonstration has fueled speculation about a potential SpaceX-Tesla merger, with betting odds on such a deal jumping from 40% to 60% by May 2027.

A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.

JPMorgan Chase's Q3 earnings missed expectations with EPS of $5.57 versus $5.93 expected and revenue of $50.17 billion versus $51.23 billion anticipated. CEO Jamie Dimon warned of multiple economic headwinds including large fiscal deficits, sticky inflation, elevated asset prices, rising interest rates, and geopolitical tensions that could impact the bank and economy. While market activity remains strong, particularly from AI spending, Dimon noted activity was already moderating in Q3.

AI "amplifies" existing cybersecurity risks toward U.S. digital infrastructure, Clayton said on "Squawk Box."

Nike's stock has plummeted over 50% as CEO Elliott Hill's turnaround strategy has failed to reverse declining sales, particularly in China where revenue dropped 26% year-over-year. With only 26% of analysts rating it a buy and competitors like On Holding and Deckers Outdoor gaining market share with stronger margins, the article suggests waiting for the new Pace cost-cutting plan to show results before investing, rather than buying into the current pessimism.

Oracle's remaining performance obligations reached a record $664 billion, up $209 billion year-over-year, with cloud infrastructure revenue growing 121% YoY. If the company converts half its backlog within 36 months and maintains current P/E multiples, a $1,000 investment could reach approximately $2,430 by 2029. However, risks include delays in data-center capacity expansion and customer concentration.

OXB, a global cell and gene therapy CDMO, has appointed Dr Joachim Kreuzburg as an Independent Non-Executive Director effective November 23, 2026. Kreuzburg brings over 20 years of life sciences leadership experience, having previously served as CEO of Sartorius AG, where he transformed the company and grew its valuation from €90 million to €14 billion through strategic acquisitions and innovation.

Lowe's stock has declined 23% year-to-date and hit a 52-week low following reduced guidance in Q2 earnings, driven by weak consumer spending on home improvement amid high mortgage rates and inflation. However, the article argues this presents a buying opportunity due to the stock's attractive P/E ratio of 16 (lowest in 3 years), strong dividend history (55 consecutive years of increases), solid free cash flow, and potential recovery when housing market conditions improve. Wall Street analysts are bullish with a median price target suggesting 36% upside.

On the campaign trail, JB Pritzker courts farmers like he's running for president  Reuters

Microsoft plans to significantly expand its custom-designed Maia chips in Azure data centers starting next year, reducing reliance on Nvidia GPUs. The company will make Maia 300 chips its primary inference system for its products and services. This shift benefits Marvell Technology, which partners on the Maia chips, while pressuring Nvidia as major cloud providers develop custom AI accelerator alternatives.

US Treasury says Japan no longer faces deflationary environment, yen level must change  Reuters

TSMC delivered record Q3 earnings with 50.9% revenue growth and expanded margins, but the stock fell 2.2% amid broader AI sector weakness. CEO warned of consumer market challenges from rising component prices and macroeconomic uncertainties, though AI chip demand remains extremely robust. The sell-off reflects investor fatigue with the AI trade despite TSMC's strong fundamentals and reasonable valuation.

CoreWeave's credit default swap spreads hit a record 1,038 basis points, signaling market concerns about potential default. While the AI infrastructure company shows impressive growth with $2.58 billion in quarterly revenue and a $104 billion backlog, it carries $51 billion in debt and posted a negative $5.7 billion free cash flow last quarter. Rising borrowing costs could threaten the company's ability to fund its expansion if lenders become unwilling to extend more capital.

The author purchased Micron Technology stock despite its 230% gain in 2026, citing the unprecedented AI-driven memory chip demand wave. Micron is reducing its cyclical business nature through long-term contracts with floor/ceiling pricing and take-or-pay agreements that lock in 35% of revenue through 2030. Supply constraints will persist through 2027-2028, supporting continued revenue growth. The author plans to monitor market conditions closely and exit if deterioration occurs.

Billionaire hedge fund manager Paul Tudor Jones warns that the current market resembles 1999 before the dot-com bubble burst, predicting 2027 will be 'really, really challenging' for stocks. While most Wall Street strategists remain optimistic with price targets around 8,700-9,000 for the S&P 500, Jones cites negative investment flows and a 'two-speed economy' driven by AI adoption as key concerns. He notes the worst flow picture for U.S. stocks since 2002, driven by IPO unlocks and secondary offerings overwhelming corporate support from buybacks and M&A.

Tesla's Cybercab robotaxi fleet in Austin has grown from fewer than 40 to over 300 vehicles in one month, with Dallas expansion planned next. While the rapid scaling demonstrates progress on Elon Musk's autonomous driving ambitions, the company still needs to prove profitability and operational economics. Regulatory scrutiny and competition from Waymo remain challenges.

ASML reported strong Q3 earnings with 55% revenue growth and raised full-year guidance, signaling robust AI-driven semiconductor demand. The company is taking orders into 2029-2030 and expects supply constraints through 2028, which benefits memory chip makers like Micron. Despite broader tech sector weakness, supply constraints in the semiconductor industry are expected to persist for years, supporting elevated chip prices.